Tesamorelin
FDA-approved GHRH analog for HIV-associated lipodystrophy
Brief Overview: Tesamorelin is an approved GHRH analog used to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not simply a generic belly-fat peptide for everyone. Evidence lens: The approved evidence is condition-specific and supported by label data. General obesity, bodybuilding, and longevity uses require separate evidence and risk assessment. How to read this: if you're new, understand that the peptide exposure is short but the endocrine effect is assessed through IGF-1 and visceral-fat outcomes over time. Once you're past the basics, monitor IGF-1, glucose/A1c, edema, malignancy history, and formulation-specific storage rules.
- Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH) developed by Theratechnologies.
- It stimulates endogenous production and release of growth hormone from the pituitary.
- It is the only FDA-approved GHRF peptide and the only FDA-approved medication for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
- New formulation, EGRIFTA WR (tesamorelin F8), FDA-approved March 25, 2025 Theratechnologies received FDA approval for a concentrated F8 formulation of tesamorelin under the trade name EGRIFTA WR.
- EGRIFTA WR is formulation-specific. Bioequivalence-style wording is not a practical interchangeability statement: EGRIFTA WR and EGRIFTA SV are not substitutable and have different doses, vial preparation, reconstitution, storage, and label PK values.
- EGRIFTA WR is replacing EGRIFTA SV in the U.S. market; The two formulations are not substitutable, dosing, vial count per dose, reconstitution protocol, and storage requirements all differ.
- Tesamorelin is a GHRH analog with an FDA-approved product context for HIV-associated lipodystrophy/visceral adipose tissue reduction. It does not belong with generic GH secretagogue wellness protocols.
Tesamorelin acts as a highly specific secretagogue for the pituitary gland:
- GHRH Receptor Agonism: It binds to GHRH receptors on pituitary somatotrophs, stimulating the natural, pulsatile release of endogenous Growth Hormone (GH).
- Lipolysis (Visceral Fat Targeting): Elevated GH acts directly on adipocytes and stimulates the production of IGF-1 in the liver. Clinical data in the approved HIV-lipodystrophy context show reduction of excess visceral adipose tissue (VAT). This is GH/IGF-1-mediated VAT reduction in a specific indication, not a literal “unique affinity” or direct fat-melting effect. Mitochondrial &
- Cognitive Support: Recent research suggests it improves mitochondrial oxidative phosphorylation in muscles and may have neuroprotective effects by reducing brain pro-inflammatory markers.
- It stimulates endogenous GH and IGF-1 through GHRH receptor signaling, leading to VAT reduction in the approved context. It does not directly melt fat independent of the GH/IGF-1 axis. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Visceral Fat Reduction: Phase III clinical trials consistently demonstrate a 15-20% reduction in VAT over 26 weeks.
- Lipid Profile Improvement: Significant reductions in triglycerides and non-HDL cholesterol have been observed, contributing to better cardiovascular health.
- Cognitive Impact: Studies in both HIV-positive and healthy elderly populations suggest improvements in executive function and memory, potentially linked to increased IGF-1 in the brain.
- Liver Health: It has been shown to reduce liver fat (intrahepatic triglycerides) by nearly 40% in patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Clinical evidence is disease-specific and stronger than most GH-axis peptides in the guide. Benefits and risks are tied to the studied HIV-lipodystrophy population and label endpoints. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: EGRIFTA SV (legacy F4, 2 mg/vial) [FDA/Approved/Label]; Route: Subcutaneous abdomen injection; Dose: Daily dose: 1.4 mg (0.35 mL) SC; Frequency: Daily; Status: Yes - FDA-approved label/product protocol for the labeled indication only.
- Protocol 2: EGRIFTA WR (new F8, 11.6 mg/vial) [FDA/Approved/Label]; Route: Subcutaneous abdomen injection; Dose: Daily dose: 1.28 mg (0.16 mL) SC; Frequency: Daily dosing from weekly-reconstituted vial; Status: Yes - FDA-approved label/product protocol for the labeled indication only.
- Protocol 3: EGRIFTA WR FDA-label formulation and dose protocol [FDA/Approved/Label]; Route: Subcutaneous (abdomen); Dose: 1.28 mg (0.16 mL) once daily; Frequency: Once daily; Timing: Administer as directed in product instructions; Rotate abdominal injection sites; Duration: Chronic use only for the labeled HIV-associated lipodystrophy indication while clinically appropriate; Max: 1.28 mg once daily per EGRIFTA WR IFU/label context; Titration/loading: No biohacker titration inserted; Product-specific labeled instructions apply; Status: Yes - FDA-approved label/product protocol for HIV-associated lipodystrophy indication only.
- EGRIFTA WR and SV are not substitutable, and label dosing is once daily SC. Community 5-on/2-off logic does not replace label instructions. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Simple plasma time until steady state: roughly 40–55 minutes by the 5-half-life rule using current label half-lives; Clinical response is not judged by maintaining tesamorelin plasma levels.
- Half-life basis: current labels report mean t½ of about 11 minutes for EGRIFTA WR after 1.28 mg SC and about 8 minutes for EGRIFTA SV after 1.4 mg SC.
- Beginner translation: plasma exposure is very short, but downstream GH/IGF-1 effects are monitored over time; Use IGF-1, glucose/A1c, adverse effects, and label response measures rather than constant peptide levels.
- Bioavailability: low absolute SC bioavailability; Label/context values do not mix across formulations.
- Delivery: subcutaneous injection into the abdomen under product-specific label instructions; EGRIFTA WR and EGRIFTA SV are not interchangeable.
- Plasma half-life is short, but IGF-1 and VAT outcomes are downstream. The label half-life and formulation distinctions apply here, not generic GHRH assumptions. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Ipamorelin: Often stacked to maximize the GH pulse. While Tesamorelin provides the GHRH signal, Ipamorelin acts on the Ghrelin receptor for a multi-pathway release.
- AOD-9604: Combined as a “belly fat shredder” stack, where AOD handles subcutaneous fat mobilization and Tesamorelin targets visceral fat.
- MOTS-c: Used together to maximize mitochondrial efficiency and metabolic resilience.
- Stacking with other GH secretagogues, GH, or IGF-1 analogs risks excessive IGF-1 and glucose effects. Combining with GLP-1s may complicate body-composition interpretation. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Side Effects: Common reactions include injection site redness (erythema), joint pain (arthralgia), and mild peripheral edema (water retention).
- Glycemic Control: It can increase blood glucose levels; Diabetic or pre-diabetic users must monitor HbA1c closely.
- Contraindications: Active malignancy (cancer), pregnancy (Category X), and disruption of the hypothalamic-pituitary axis (e.g., history of pituitary tumors).
- Watch IGF-1 elevation, glucose intolerance/diabetes, edema, arthralgia, injection reactions, and malignancy contraindication/caution contexts. It is an endocrine drug, not merely a peptide supplement. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- IGF-1 Levels: Monitored to ensure they stay within a physiological range (typically aiming for the upper quartile of the age-matched range).
- Fasting Glucose: To screen for the development of insulin resistance.
- Waist-to-Hip Ratio: A primary physical marker for the reduction of visceral adiposity.
- Track IGF-1, glucose/A1c, waist/VAT endpoints, edema, joint symptoms, and contraindications such as active malignancy or pregnancy per label context. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Original Egrifta approved 2010 for HIV-associated lipodystrophy. EGRIFTA WR (tesamorelin F8) approved March 25, 2025 for the same indication. EGRIFTA SV is being phased out during a transitional supply period. Not approved for weight loss in any population, this remains a critical off-label caveat for non-HIV users.
- WADA: Prohibited (S2).
- Availability: Specialty-pharmacy distribution. The only FDA-approved growth-hormone-releasing-factor peptide.
- Tesamorelin has FDA-approved formulations with specific dosing and reconstitution instructions. Approved-product status does not generalize to compounded substitutes. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.